[关键词]
[摘要]
以免疫检测点抑制剂（ICI）为代表的免疫治疗是晚期非小细胞肺癌（NSCLC）治疗的重要手段之一，它们通过释放免疫检查点介导的免疫抑制，恢复机体免疫平衡，提高了抗肿瘤有效率，使晚期NSCLC 患者的预后得到了显著改善。然而，晚期NSCLC的ICI 治疗过程中仍然存在许多尚未解决的问题。本文将围绕ICI 治疗晚期NSCLC的全程管理展开论述，包括ICI 治疗疗效预测、特殊人群筛查、药物选择、新型药物研发，以及ICI 治疗停止后的重启、耐药及免疫相关不良反应（irAE）的处理等，以期为晚期NSCLC患者的ICI治疗提供指导。
[Key word]
[Abstract]
Immunotherapy based on immune checkpoint inhibitor (ICI) has become the main treatment strategy for advanced non-small cell lung cancer (NSCLC)．By releasing immune checkpoint mediated immunosuppression, ICI restores the body's immune balance, improves the anti-tumor response rate, and significantly improves the prognosis of patients with advanced NSCLC. However, many problems remain unsolved in ICI treatment for advanced NSCLC. The present article will focus on the full-course management of ICI immunotherapy in advanced NSCLC patients, including prediction of immunotherapy efficacy, special patients screening before the initiation of ICI therapy, choice of the ICI drugs, development of new generation ICI drugs, restart of ICI immunotherapy after immune-related adverse event, ICI resistance, and the management of immune-related adverse events, in order to provide guidance for immunotherapy for advanced NSCLC patients.
[中图分类号]
[基金项目]
国家自然科学基金面上项目（No. 81572875）；山东省自然科学基金面上项目（No. ZR202102190539）；CSCO 领航肿瘤研究基金项目（No. Y-2019AZMS-0440）；CSCO默沙东肿瘤研究基金项目（No. YMSD2020-0350）；吴阶平医学研究基金项目（No. 320.6750.2020-12-16）
